These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8632408)

  • 1. Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas.
    Castro JL; Ball RG; Broughton HB; Russell MG; Rathbone D; Watt AP; Baker R; Chapman KL; Fletcher AE; Patel S; Smith AJ; Marshall GR; Ryecroft W; Matassa VG
    J Med Chem; 1996 Feb; 39(4):842-9. PubMed ID: 8632408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
    Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
    J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
    Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419.
    Tabuchi S; Ito H; Sogabe H; Kuno M; Kinoshita T; Katumi I; Yamamoto N; Mitsui H; Satoh Y
    Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):1-15. PubMed ID: 10705468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
    J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
    Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
    J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New 1,4-benzodiazepin-2-one derivatives as gastrin/cholecystokinin-B antagonists.
    Satoh M; Kondoh Y; Okamoto Y; Nishida A; Miyata K; Ohta M; Mase T; Murase K
    Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2159-67. PubMed ID: 8582018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of 11C-labeled nonpeptide antagonists for cholecystokinin receptors: [11C]L-365,260 and [11C]L-365,346.
    Haradahira T; Inoue O; Kobayashi K; Suzuki K
    Nucl Med Biol; 1998 Apr; 25(3):203-8. PubMed ID: 9620624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of N-(5-methyl-3-oxo-1,2- diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-N'-phenylureas as cholecystokinin antagonists.
    Lattmann E; Sattayasai J; Boonprakob Y; Lattmann P; Singh H
    Arzneimittelforschung; 2005; 55(5):251-8. PubMed ID: 15960423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
    Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
    J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
    Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
    Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential blockade of cholecystokinin-8S-induced increases in aspartate and glutamate levels by the CCK(B) receptor antagonist, L-365,260, in rat brain.
    Ge J; Long SK; Kilpatrick IC
    Eur J Pharmacol; 1998 Mar; 345(2):163-70. PubMed ID: 9600632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.
    van der Bent A; Blommaert AG; Melman CT; IJzerman AP; van Wijngaarden I; Soudijn W
    J Med Chem; 1992 Mar; 35(6):1042-9. PubMed ID: 1552499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a series of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation.
    Kopin AS; McBride EW; Chen C; Freidinger RM; Chen D; Zhao CM; Beinborn M
    Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5525-30. PubMed ID: 12697901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular design of potent specific antagonists for the gastrin and cholecystokinin receptors.
    Evans BE
    Z Gastroenterol Verh; 1991 Mar; 26():269-71. PubMed ID: 1714170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
    Martín-Martínez M; Bartolomé-Nebreda JM; Gómez-Monterrey I; González-Muñiz R; García-López MT; Ballaz S; Barber A; Fortuño A; Del Río J; Herranz R
    J Med Chem; 1997 Oct; 40(21):3402-7. PubMed ID: 9341915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
    Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
    Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCK receptor antagonists.
    Dunlop J
    Gen Pharmacol; 1998 Oct; 31(4):519-24. PubMed ID: 9792209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cholecystokinin-B receptor antagonist L-740,093 produces an insurmountable antagonism of CCK-4 stimulated functional response in cells expressing the human CCK-B receptor.
    Dunlop J; Pass I; Ennis C
    Neuropeptides; 1998 Apr; 32(2):157-60. PubMed ID: 9639254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.